Sugi Predict

Sugi Predict / Targets / AOC3

AOC3

Amine oxidase [copper-containing] 3 · Q16853 · AOC3 on Sugi Atlas →

103,066 patent compounds predicted against AOC3, 45,565 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10552 SCHEMBL10552 0.44 12/20
SCHEMBL42838 SCHEMBL42838 0.48 8/20
Etafedrine Etafedrine (SCHEMBL123128) 0.61 7/20
SCHEMBL25159 SCHEMBL25159 0.56 6/20
Phenylpropanol Phenylpropanol (SCHEMBL56673) 0.54 6/20
SCHEMBL82461 SCHEMBL82461 0.52 6/20
SCHEMBL82462 SCHEMBL82462 0.52 6/20
SCHEMBL186279 SCHEMBL186279 0.52 6/20
Fenipentol Fenipentol (SCHEMBL21837) 0.48 6/20
SCHEMBL29169 SCHEMBL29169 0.38 6/20
SCHEMBL163710 SCHEMBL163710 1.00 5/20
Methylephedrine Methylephedrine (SCHEMBL99673) 0.70 5/20
Methylephedrine Methylephedrine (SCHEMBL99674) 0.70 5/20
Methylephedrine Methylephedrine (SCHEMBL68363) 0.68 5/20
SCHEMBL2021 SCHEMBL2021 0.58 5/20
SCHEMBL147501 SCHEMBL147501 0.58 5/20
SCHEMBL175554 SCHEMBL175554 0.58 5/20
SCHEMBL75867 SCHEMBL75867 0.56 5/20
SCHEMBL24750 SCHEMBL24750 0.54 5/20
SCHEMBL42066 SCHEMBL42066 0.54 5/20

Clinical trials — most relevant to AOC3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Improving Outcomes in Neonatal Abstinence Syndrome PHASE3COMPLETED
Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing. PHASE1/PHASE2COMPLETED
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease PHASE2COMPLETED
Safety Study of High Doses of Zinc in ALS Patients PHASE1/PHASE2COMPLETED
Copper Histidine Therapy for Menkes Diseases PHASE1/PHASE2COMPLETED
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) PHASE1/PHASE2COMPLETED
Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study PHASE1WITHDRAWN
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns nanCOMPLETED
Molecular Epidemiology of Parkinson's Disease nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Mechanisms for Individual Differences in Hypertension in Obstructive Sleep nanCOMPLETED
Personalizing Preterm Neonatal Transfusions With Fetal Hemoglobin-Enriched Cord Blood nanNOT_YET_RECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Parkinson's Diseases Susceptibility Genes and Pesticides nanCOMPLETED
Family Blood Pressure Program - GENOA nanCOMPLETED
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD) nanCOMPLETED
Optimal Approach for Analysis of Case-Control Genetic Association Studies nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC nanCOMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Genetics of Obsessive-Compulsive Disorder nanCOMPLETED
Vitamin C Level Effect in Orthognathic Surgery nanCOMPLETED
Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans nanCOMPLETED
Mechanisms of Action of Acetaminophen nanCOMPLETED
Race And CPAP Effectiveness nanCOMPLETED
Environmental Epidemiology of Essential Tremor nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AOC3 binder may also engage these)

ProteinNameSimilarity
O70423 — 1.000 O70423 →
Q5R9I0 — 1.000 Q5R9I0 →
O08590 — 1.000 O08590 →
Q9TTK6 — 1.000 Q9TTK6 →
AOC1 Diamine oxidase [copper-containing] 1.000 landscape →
AOC2 Amine oxidase [copper-containing] 2 1.000 landscape →
P36633 — 1.000 P36633 →
Q29437 — 1.000 Q29437 →
O46406 — 1.000 O46406 →
Q812C9 — 1.000 Q812C9 →
Q8JZQ5 — 0.999 Q8JZQ5 →
Q9TRC7 — 0.999 Q9TRC7 →
Q9M2B9 — 0.983 Q9M2B9 →
Q5RDJ3 — 0.982 Q5RDJ3 →
Q9DBX3 — 0.982 Q9DBX3 →
Q9UGT4 — 0.981 Q9UGT4 →
O54782 — 0.981 O54782 →
Q28949 — 0.980 Q28949 →
O00115 — 0.978 O00115 →
Q09200 — 0.978 Q09200 →
ENGASE Cytosolic endo-beta-N-acetylglucosaminidase 0.978 landscape →
MAN2B2 Epididymis-specific alpha-mannosidase 0.978 landscape →
Q8H1H9 — 0.978 Q8H1H9 →
A6QQ07 — 0.977 A6QQ07 →
Q0V8J4 — 0.977 Q0V8J4 →
P15101 — 0.977 P15101 →
Q9JHA8 — 0.977 Q9JHA8 →
Q5T197 — 0.977 Q5T197 →
P2RX5 P2X purinoceptor 5 0.977 landscape →
Q01634 — 0.977 Q01634 →